Check for updates

OPEN ACCESS

EDITED BY Wei Wang, Renmin Hospital of Wuhan University, China

REVIEWED BY Huanghui Wu, Shanghai Fourth People's Hospital, China Yangzi Zhu, Xuzhou Central Hospital, China

*CORRESPONDENCE Fei Li ⊠ leagcen@126.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 10 October 2024 ACCEPTED 26 December 2024 PUBLISHED 15 January 2025

CITATION

Yang Q, Li C, Ye M, Zhou X, Li W and Li F (2025) Effect of central sensitization on postoperative cognitive dysfunction in total knee arthroplasty patients: a retrospective study. *Front. Neurol.* 15:1509197.

doi: 10.3389/fneur.2024.1509197

COPYRIGHT

© 2025 Yang, Li, Ye, Zhou, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effect of central sensitization on postoperative cognitive dysfunction in total knee arthroplasty patients: a retrospective study

Qiqi Yang^{1,2†}, Chunning Li^{1†}, Min Ye², Xinhua Zhou^{1,3}, Weiran Li¹ and Fei Li^{1,4}*

¹Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China, ²The First Clinical Medical School, Anhui University of Chinese Medicine, Hefei, China, ³First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁴Hefei Southeast Orthopedics Hospital, Hefei, China

Background: Postoperative cognitive dysfunction (POCD) is a common complication after total knee arthroplasty (TKA), impacting recovery and quality of life. This study aims to investigate central sensitization (CS) as an independent risk factor for POCD to improve preoperative screening and postoperative interventions.

Methods: A retrospective analysis was conducted on 142 TKA patients from January 2020 to May 2024 across three hospitals. Data were collected at six time points: preoperatively (T0), intraoperatively (T1), and postoperatively on days 1 (T2), 3 (T3), 7 (T4), and 30 (T5). Patients were classified into CS (CSI \geq 40) and non-CS (CSI < 40) groups according to Central Sensitization Inventory (CSI) score. Cognitive function and POCD incidence were assessed with the Mini-Mental State Examination (MMSE), and knee recovery with the Knee Injury and Osteoarthritis Outcome Score (KOOS). Logistic regression was used to identified risk factors for POCD.

Results: The overall incidence of POCD at T5 was 19.72%, with a significantly higher rate in CS group (30.91%) compared to non-CS group (12.64%) (p = 0.008). MMSE scores declined significantly in both groups at T2 and T3 compared to T0 (p < 0.05), with CS group showing consistently lower scores than non-CS group at T2-T5 (p < 0.05). KOOS scores revealed that CS group had worse pain and quality of life scores at T0, T4, and T5 compared with non-CS group (p < 0.05). Logistic regression revealed that CS, cerebrovascular disease, intraoperative hemorrhage, and preoperative MMSE were associated with the risk of POCD (p < 0.05).

Conclusion: CS is a significant risk factor for POCD following TKA, adversely affecting recovery in terms of pain and quality of life. Prospective studies are warranted to validate findings and develop targeted interventions.

KEYWORDS

central sensitization, postoperative cognitive dysfunction, total knee arthroplasty, retrospective study, Mini-Mental State Examination, Knee Injury and Osteoarthritis Outcome Score

1 Introduction

Total Knee Arthroplasty (TKA) is widely regarded as the most effective surgical intervention for managing end-stage knee osteoarthritis (KOA), offering significant pain relief and functional restoration (1, 2). Despite advancements in surgical techniques, prosthetic knee designs (3), and postoperative rehabilitation protocols, approximately 10–40% of patients may still develop postoperative cognitive dysfunction (POCD) (4, 5). POCD is a common postoperative syndrome characterized by cognitive impairments, including deficits in memory, intellectual ability, and executive function (6). This complex condition often persists beyond the expected recovery period from anesthesia, contributing to prolonged hospital stays, increased healthcare costs, greater care requirements, as well as elevated morbidity and mortality (7–9).

The precise mechanisms underlying POCD remain poorly understood, emerging evidence points to a potential role of central sensitization (CS) in its pathogenesis (10). CS, a pathological condition frequently observed in chronic pain patients, is marked by a heightened excitability of the central nervous system (CNS) triggered by persistent peripheral nociceptive stimuli, leading to exaggerated pain responses even from subthreshold or normal sensory input (11). CS has been shown to a significant risk factor for persistent pain and patient dissatisfaction after TKA (12, 13). However, CS not only intensifies pain perception in patients undergoing TKA, but also potentially compromises cognitive function through a cascade of neuroinflammatory processes (14, 15). Studies suggest that patients with CS exhibit a significantly lowered pain threshold, a phenomenon closely linked to microglial activation and the release of pro-inflammatory cytokines such as IL-6 and TNF- α within the CNS (16–18). These inflammatory mediators are thought to be key drivers of cognitive decline (19, 20). This suggests that CS is not only a primary mechanism responsible for chronic postoperative pain but also a contributor to POCD through sustained neuroinflammation and altered neuroplasticity.

Notably, the presence of CS in TKA patients is often accompanied by preoperative chronic pain and psychosocial factors, such as anxiety, depression, and sleep disturbances, all of which are themselves closely linked to the occurrence of POCD (21, 22). As such, CS is considered to be a critical risk factor for POCD following TKA. Although previous studies have explored the impact of CS on postoperative pain and functional recovery, systematic research into its relationship with POCD remains very limited.

Given this, the study aims to conduct a retrospective analysis to investigate the impact of preoperative CS on POCD in TKA patients. Patients will be stratified based on their preoperative Central Sensitization Inventory (CSI) scores, and the correlation between CS and POCD will be assessed. The findings from this study are expected to offer new insights for preoperative screening, and postoperative management, ultimately reducing the incidence of POCD and improving patient outcomes.

2 Materials and methods

2.1 Study design

This study is a multi-center, retrospective cohort investigation aimed at evaluating the impact of CS on POCD in patients undergoing TKA. Clinical data were sourced from medical records at the First Affiliated Hospital of Bengbu Medical College, the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, and Hefei Southeast Orthopedics Hospital. The study adhered to the STROBE guidelines and received ethical approval from the Institutional Review Board (2023-zj-40). As all data were de-identified, informed consent from patients was waived.

2.2 Participants

This study retrospectively analyzed patients who underwent TKA at the aforementioned three hospitals between January 1, 2020, and May 31, 2024. The inclusion criteria were as follows: (1) age \geq 55 years; (2) diagnosed with end-stage KOA; (3) undergoing primary unilateral TKA; and (4) having complete CSI scores. Exclusion criteria included: (1) simultaneous bilateral TKA or revision TKA; (2) a history of central nervous system or psychiatric disorders; (3) severe sensory impairments affecting vision or hearing; (4) severe comorbidities involving the heart, brain, or lungs; (5) preoperative Mini-Mental State Examination (MMSE) score \leq 23; (6) use of cognitive-impairing medications pre- or post-surgery (e.g., sedatives, anti-inflammatory drugs, psychotropics); and (7) incomplete clinical records.

2.3 Data collection

We collected comprehensive demographic and clinical data from patients meeting the study criteria, including age, gender, BMI, educational level, American Society of Anesthesiologists (ASA) classification, smoking, drinking, duration of KOA, and comorbidities such as hypertension, hyperlipidemia, diabetes, coronary heart disease, cerebrovascular disease, and chronic obstructive pulmonary disease. Data were collected at the following time points: preoperatively (T0), intraoperatively (T1), on postoperative day 1 (T2), postoperative day 3 (T3), postoperative day 7 (T4), and postoperative day 30 (T5). At T0, CSI scores were recorded to assess the state of CS, and preoperative hemoglobin levels were documented to evaluate the presence of anemia. At T1, the anesthesia methods, duration of anesthesia, duration of surgery, and intraoperative blood loss were documented. At T2-T5, MMSE scores were recorded to assess cognitive function and determine the incidence of POCD, while the Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to evaluate postoperative recovery. Although MMSE is not universally a routine clinical assessment item for TKA patients, its inclusion in this study reflects institutional efforts to systematically monitor and manage POCD. The MMSE data were collected as part of the standard cognitive assessments implemented at the participating institutions and were consistently recorded in the hospitals' medical records by trained clinical staff.

Abbreviations: POCD, Postoperative cognitive dysfunction; TKA, total knee arthroplasty; CS, Central sensitization; KOA, Knee osteoarthritis; CSI, Central sensitization inventory; MMSE, Mini-Mental State Examination; KOOS, Knee Injury and Osteoarthritis Outcome Score; ASA, American society of anesthesiologists; OR, Odds ratios; ADL, Activities of daily living; QoL, Quality of life.

2.4 Assessment tools

2.4.1 Central sensitization assessment

The Central Sensitization Inventory (CSI) was used preoperatively to assess the CS status of patients. The CSI is a validated, patientreported questionnaire designed to evaluate symptoms associated with CS. It has been demonstrated to be a reliable, consistent, and effective tool for quantifying the severity of CS-related symptoms (23). The inventory includes 25 items, each scored from 0 to 4, with a total score ranging from 0 to 100. Based on established criteria (24, 25), a score of 40 or higher indicates the presence of CS, while a score below 40 suggests the absence of CS. In this study, patients were categorized into a CS group (CSI \geq 40) and a non-CS group (CSI < 40).

2.4.2 Cognitive function assessment

The MMSE scores was used to evaluated cognitive function (26). It primarily evaluates five cognitive domains: orientation, registration, attention and calculation, recall, and language abilities. The MMSE consists of 24 items with a total score of 30, where higher scores indicate better cognitive function. In this study, POCD was defined based on the changes in MMSE scores observed on postoperative day 30 (T5). Specifically, POCD was defined as a decline of 1 or more standard deviations (SD) in the postoperative MMSE score compared to the preoperative score. A reduction of 1–2 SD indicates postoperative mild neurocognitive disorder (NCD), while a reduction greater than 2 SD indicates postoperative major neurocognitive disorder (27).

2.4.3 Knee function assessment

The KOOS is a patient-reported outcome measurement system used to evaluate short-term and long-term symptoms and function in individuals after TKA. The score consisted of five separately scored subscales: pain, symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec), and knee-related quality of life (QoL) (28). The KOOS scale consists of 42 items with a total score ranging from 0 to 100, where higher scores indicate better functional recovery.

2.5 Statistical analysis

All statistical analyses were performed using SPSS version 26.0. Continuous variables are presented as mean ± standard deviation (SD), while categorical variables are expressed as frequencies and percentages. For continuous variables measured at multiple time points (e.g., MMSE and KOOS scores at preoperative and various postoperative intervals), repeated measures analysis of variance (ANOVA) was employed to assess both within-group and betweengroup trends. Independent samples t-tests were conducted to compare mean values between two groups, whereas paired t-tests were utilized to evaluate changes within the same group at two distinct time points. Categorical variables were analyzed using the chi-square test. To identify potential risk factors for POCD, both univariate and multivariate logistic regression analyses were performed, and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated. All statistical tests were conducted with a significance level set at *p* < 0.05.

3 Results

3.1 Patient demographics and clinical characteristics

A total of 294 patients scheduled for TKA were initially recruited for the study. However, 152 patients were excluded based on the following criteria: age < 55 years, revision TKA, non-end-stage KOA, preoperative MMSE score < 24, history of psychiatric disorders, hearing impairment, preoperative sedative use, and incomplete clinical data (n = 54). Ultimately, 142 patients were included in the final analysis. Figure 1 illustrates the patient selection flowchart.

Among the 142 patients enrolled in the study, 55 were assigned to the CS group (CSI \geq 40), and 87 to the non-CS group (CSI < 40). Analysis of baseline data revealed no significant differences between the groups in terms of age, gender, BMI, education level, smoking, drinking, ASA classification, duration of KOA, comorbidities, preoperative hemoglobin, anemia, preoperative MMSE, operation time, intraoperative hemorrhage, anesthesia type, and anesthesia time (all p > 0.05) (Table 1).

3.2 Comparison of the incidence of POCD

The overall incidence of POCD on 30 days postoperatively was 19.72% (28/142). The incidence in the CS group was 30.91% (17/55), significantly higher than 12.64% (11/87) in the non-CS group (p = 0.008), indicating a strong correlation between central sensitization and the overall occurrence of POCD. However, when examining the severity of POCD, no significant differences were observed between the two groups regarding the proportions of mild and major cases (p>0.05). In the CS group, 12 cases were classified as postoperative mild NCD and 5 as major, while in the non-CS group, 9 cases were mild and 2 were postoperative major NCD. These findings suggest that central sensitization primarily influences the overall incidence of POCD rather than its severity (Figure 2).

3.3 Comparison of MMSE scores

Repeated measures ANOVA indicated a significant main effect of group on MMSE scores (F = 45.08, p < 0.001), indicating a notable difference in cognitive recovery between the CS group and the non-CS group. The main effect of time was also significant (F = 60.68, p < 0.001), reflecting a trend of change in MMSE scores over time. Moreover, the interaction between time and group was significant (F = 3.443, p = 0.009), suggesting that the two groups exhibited different trends in postoperative cognitive recovery.

Paired comparisons within each group showed significant differences in MMSE scores for both the CS group and the non-CS group at T2 and T3 compared to T0 (p < 0.05). Between-group comparisons revealed significant differences in MMSE scores at all time points except T0 (p < 0.05). These findings suggest that patients in the CS group exhibited a marked delay in postoperative neurocognitive recovery, particularly during the early recovery phase (Table 2; Figure 3).



3.4 Comparison of KOOS scores

Repeated measures ANOVA indicated a significant main effect of group on the pain and QoL subdomains of the KOOS scores (F = 85.26, p < 0.001; F = 85.88, p < 0.001), while no significant main effects were observed for symptoms, ADL, and Sport/Rec subdomains (F = 3.797, p = 0.052; F = 3.294, p = 0.07; F = 0.841, p = 0.360). This suggests that there were significant differences between the CS group and non-CS group in pain perception and quality of life recovery, but no significant differences in symptoms, daily activities, or sports/recreation. The main effect of time was significant across all five KOOS subdomains (F = 209.4, p < 0.001; F = 480.0, p < 0.001; F = 659.3, p < 0.001; F = 911.5, p < 0.001; F = 651.4, p < 0.001), indicating that patients experienced significant improvements in all KOOS subdomains over time. Furthermore, the interactions between time and group were observed for both pain and QoL scores (F = 10.74, p < 0.001; F = 6.201, p < 0.001), suggesting that the two groups exhibited different trends in postoperative pain relief and quality of life recovery.

Paired comparisons within each group showed significant differences in all KOOS subdomains at all postoperative time points compared to T0 in both the CS and non-CS groups (p < 0.05), indicating overall recovery in pain, symptoms, daily activities, sports/recreation, and quality of life following TKA. Between-group comparisons revealed that the CS group had significantly lower pain and quality of life scores at T0, T4, and T5 compared to the non-CS group (p < 0.05), indicating a marked delay in postoperative pain relief and quality of life recovery in the CS group (Table 3; Figure 4).

TABLE 1 Comparison of baseline demographic and clinical characteristics.

Educational level, n (%) Educational level, n (%) Below high school 37 (67,27%) 47 (54,02%) 2.448 0.118 High school and above 18 (32,73%) 40 (45,98%) 2.448 0.118 Smoking, n (%) 13 (23,64%) 2.7 (31.03%) 0.912 0.340 Drinking, n (%) 19 (34,55%) 30 (34,48%) 0.912 0.994 ASA classification, n (%) 11 12.64%) 0.912 0.994 I 7 (12,73%) 11 (12.64%) 0.0002 0.989 II 10 (18.18%) 23 (26.44%) 1.287 0.257 Duration of KOA, years (~x ± s) 9.71 ± 7.81 8.20 ± 6.59 1.237 0.218 Combined underlying diseases, n (%) 1.199 0.274 Hypertension 22 (40.00%) 27 (31.03%) 1.199 0.274 Hypertension 22 (40.00%) 27 (31.03%) 0.450 0.502 Diabetes 14 (25.45%) 25 (28.74%) 0.450 0.502 Diabetes 14 (25.45%) 5 (9.09%) 1.378	Variables	CS group (<i>n</i> = 55)	Non-CS group (<i>n</i> = 87)	t/χ^2	<i>p</i> value
Male20(47.2%)45(51.72%)0.0.670.065Fenale29(52.7%)44(48.2%)0.0470.045BAIL kgarl (* 1 x h)26.3 1 ± 3.0427.3 1 ± 3.080.045Elactional (* 1 x h)20.3 1 ± 3.040.0180.018Tigh school and above18 (0.27%)40 (0.59%)2.4480.118Tigh school and above13 (0.25%)0.01 (0.59%)0.0120.094Stackansletzon, (%)10 (0.45%)0.0120.0940.012Act dassification, (%)10 (0.45%)0.0120.0940.012Sta dassification, (%)10 (0.15%)0.0120.0920.989II7 (0.27%)11 (12.6%)0.0020.989II10 (0.18%)0.53 (0.42%)0.0230.023Daration of KOA, years (* ± e)0.71 (2.7%)1.0240.023Daration of KOA, years (* ± e)0.12 (0.09%)0.23 (0.49%)0.1370.024Hyperlpidenia10 (0.18%)1.61 (0.39%)0.1920.024Daration of KOA, years (* ± e)0.24 (0.09%)1.1020.0240.024Hyperlpidenia10 (0.18%)1.61 (0.39%)0.0340.0240.024Hyperlpidenia10 (0.18%)1.01 (0.45%)0.0240.0240.024Coronary heart disease10 (0.25%)1.01 (0.45%)0.0240.0240.024Coronary heart disease10 (0.25%)1.01 (0.45%)0.0240.0240.024Coronary heart disease10 (0.25%)1.01 (0.45%)0.0240.024<	Age, years $(-x \pm s)$	67.07 ± 5.89	65.64 ± 4.82	1.579	0.117
Fenale129(527%)42(482%)0.0267BMI, kg/m² (*x.±)26.31.3.98272.4±.3.681.4160.159Edecringle school37(62.7%)47(54.02%)2.4480.118Below high school37(62.7%)40(45.9%)2.4480.118Smsking, r(%)1013(23.64%)20120.03400.012Drinkng, n(%)1013(23.64%)30(34.48%)0.0120.0340Smsking, r(%)71(27%)111(1.64%)0.0120.032I71(27%)1.01(1.64%)0.0780.027J60.016(1.84%)2.32(64%)1.2870.237III101(8.18%)6.23 (6.64%)1.2870.218Duration KOA, yan (*±)9.71±7.818.20±6.591.0270.218Phyperkinding disease, n(%)110(18.18%)106(18.39%)0.0040.0502Diabetes101(8.18%)106(18.39%)0.0400.0502Domined muderlying disease, n(%)111(2.64%)0.04500.027Phyperkindie101(8.18%)101(8.18%)0.0400.0502Domined muderlying disease, n(%)111(2.64%)0.04500.052Diabetes101(8.18%)101(8.18%)0.0520.0514Chronic obstructive pulmonary10255 ±1.49%10.126.4%)0.052Chronic obstructive pulmonary10212.555 ±1.49%10.126.4%)0.0214Appendix MidSe, scores (*±)1212.62%)3.13.650.028Chronic obstructive pulmonary1120.00%)10.1290.256Chronic obstruct	Gender, <i>n</i> (%)				'
BML kg/n² (x±s)2631±3982724±3.681.1460.199Educational level, n (%)377(672%)475(502%)2.4480.118High school and above18103273%40104598%0.9120.940Stokakn, n (%)131(32.64%)27(10.9%)0.9120.949Drinking, n (%)191(34.5%)301(448%)0.9120.949Affactastification, n (%)71(17.9%)111(12.64%)0.00020.989II381 (69.09%)353 (69.29%)1.2370.237Dratton of KOA, years (x±s)0.912 1.230.2370.237Dratton of KOA, years (x±s)0.217 1.230.2370.237Dratton of KOA, years (x±s)10.1280.1980.237Dratton of KOA, years (x±s)10.1280.4280.927Dratton of KOA, years (x±s)11280.4280.928Dratton of KOA1.2780.4280.29	Male	26 (47.27%)	45 (51.72%)	0.267	0.605
Educational level, n (%) Unitary instance Below high school 37 (6727%) 47 (54.02%) 2.448 0.118 High school ad above 18 (32.75%) 40 (45.96%) 2.448 0.118 Smoking, n (%) 13 (23.64%) 27 (11.03%) 0.912 0.944 Smoking, n (%) 13 (23.64%) 27 (11.03%) 0.912 0.949 ASA classification, n (%) 7(12.75%) 11 (12.64%) 0.0002 0.989 II 7 (12.75%) 11 (12.64%) 0.0002 0.989 III 7 (12.75%) 13 (23.64.64) 0.0002 0.989 III 0.10 (18.18%) 23 (26.44%) 1.127 0.218 Combined underlying disease, n (%) 111 0.244 0.950 Duration of KOA, syars (* * *) 9.21 (21.05%) 1.199 0.274 Hyperleijdemia 10 (18.18%) 16 (18.19%) 0.004 0.950 Dabtes 14 (23.45%) 26 (8.05%) 1.198 0.214 Coronary bear disease 5 (9.09%) 111 (12.64%) 0.0425 <	Female	29 (52.73%)	42 (48.28%)	0.267	0.605
Helow high school and above17 (76 27%)47 (54.02%)2.4480.118High school and above18 (32.73%)40 (45.98%)2.4480.118Smoking, n (%)13 (32.64%)22 (31.03%)0.9120.940Drinking, n (%)0.9120.9340.9120.941Smoking, n (%)11 (32.64%)22 (31.03%)0.9120.941ASA classification, n (%)7 (12.73%)11 (12.64%)0.00020.989II7 (12.73%)11 (12.64%)0.9780.0323III101 (18.18%)123 (24.44%)1.2870.237Daration of KOA, years (x ± s)0.912 (24.00%)22 (31.03%)0.9780.218Daration of KOA, years (x ± s)22 (40.00%)22 (31.03%)0.0410.241Daration of KOA, years (x ± s)22 (40.00%)11 (12.64%)0.0420.241Daration of KOA, years (x ± s)22 (40.00%)11 (12.64%)0.0400.032Diration of KOA, years (x ± s)12 (40.00%)16 (13.39%)0.0410.241Diration of KOA, years (x ± s)12 (24.00%)10 (12.64%)0.4550.624Diration of KOA, years (x ± s)11 (20.0%)11 (12.64%)0.4550.624Diration of Lipyeripicdemizer11 (20.0%)11 (21.84%)0.0430.031Diration of Lipyeripicdemizer11 (20.0%)13 (3.45%)0.0230.088Drono of Lipyeripicdemizer11 (21.0%)1.190.290Diration of Lipyeripicdemizer1.1190.2900.116Diration of	BMI, kg/m ² ($^{-}x \pm s$)	26.31 ± 3.98	27.24 ± 3.68	1.416	0.159
High school and above18 (32.73%)40 (45.98%)2.4480.118Smoking, n (%)13 (32.64%)27 (31.03%)0.9120.340Drinking, n (%)19 (34.55%)30 (34.48%)0.9120.994ASA classification, n (%)7 (12.73%)11 (12.64%)0.00020.939I7 (12.73%)11 (12.64%)0.00220.939JI10 (18.18%)2.5 (60.92%)0.9020.257Duration of KOA, years (x ± a)9.71 ± 7.818.20 ± 6.591.2370.218Combined underlying diseases, n (%)7 (12.73%)6 (16.13.3%)0.0020.959Hyperhipdenia10 (18.18%)2.5 (28.74%)0.4590.952Dabedes7 (12.73%)6 (6.90%)1.1380.241Babeefs11 (12.64%)0.6420.5140.592Coronary heart disease7 (12.73%)6 (6.90%)1.3780.241Cronbary heart disease7 (12.73%)6 (4.90%)1.3780.241Cronbary heart disease5 (9.09%)11 (12.64%)0.4250.514Cronbary heart disease5 (9.09%)11 (12.64%)0.6280.592Properative bemoglobin, g/L (x ± s)13.255 ± 14.9913.293 ± 18.560.1280.698Properative bemoglobin, g/L (x ± s)13.255 ± 14.9913.293 ± 18.560.1280.698Properative MSR scores (x ± s)2.784 ± 1.102.810 ± 0.8551.6240.697210 min12 (12.18%)2.62.98%)1.1190.290≥ 120 min12 (12.05%)<	Educational level, <i>n</i> (%)				
Norking, n (%)13 (23.64%)27 (31.0%)0.9120.340Drinking, n (%)19 (34.55%)30 (34.48%)0.9120.994ASA classification, n (%)I7 (12.73%)11 (12.64%)0.00020.989II38 (69.09%)53 (60.92%)0.9780.323III0.01 (18.18%)23 (26.44%)1.2870.218Daration of KOA, years (x ± s)0.2 (40.00%)27 (31.03%)1.1990.274Combined underlying diseases, n (%)1.1970.0240.959Hyperlipidemia10 (18.18%)16 (18.39%)0.0040.959Diabetes14 (25.45%)25 (28.74%)0.0450.524Coronary heart disease75 (90%)11 (12.04%)0.0680.794Crectoroxacilar disease75 (90%)13 (23.5 ± 14.9913.233 ± 18.560.1280.899Creative hemoglobin, g/L (x ± s)32 (54.5%)32 (45.5%)0.1280.690Creative hemoglobin, g/L (x ± s)12 (21.82%)26 (29.89%)1.1190.290Intraopentive hemoglobin, g/L (x ± s)12 (21.82%)61 (70.11%)1.029Creative hemoglobin, g/L (x ± s)12 (21.82%)61 (70.11%)0.231Creat	Below high school	37 (67.27%)	47 (54.02%)	2.448	0.118
Drinking. n (%)0.9(34.5%)0.9(34.4%)0.9120.994ASA classification, n (%)I7(12.73%)1.1(12.64%)0.00020.989II3.8 (69.09%)5.5 (60.02%)0.9780.033III0.0(1.12.64%)0.2570.257Daration of KOA, years (x ±)0.0(1.12.64%)1.2870.257Daration of KOA, years (x ±)22 (0.00%)22 (1.03%)1.1990.224Combined underlying diseases, n (%)22 (0.00%)1.016(18.3%)0.0040.999Diabetes1.0 (18.18%)1.0 (18.3%)0.0040.927Diabetes1.0 (18.18%)1.0 (18.3%)0.04500.052Coronary heart disease7.1(2.73%)6.(6.90%)1.13780.241Cerebrowacular disease5.(9.0%)1.11(2.64%)0.4520.514Cronoic obstructive pulmonary1.12.00%)1.112.24%)0.0680.794Preoperative Mongoloin, g1(x±a)1.35.5±14.991.32.3±18.560.12.800.0101Preoperative MMSE, scores (x ± s)3.65.5%)3.64.5%)3.02.180.02310.209212.0 min1.2(12.82%)2.6(29.89%)1.1190.2900.292220 mL4.17(0.00%)2.12.61.4%)0.3310.55.52.20 mL1.12.0%)2.12.61.4%)0.4330.55.52.20 mL1.12.0%)2.12.61.4%)0.4330.55.52.20 mL1.12.0%)2.12.61.4%)0.43.10.55.52.20 mL1.12.0%)2.12.18%)0.43.10.55	High school and above	18 (32.73%)	40 (45.98%)	2.448	0.118
ASA classification, n (%)I7 (12,73%)11 (12,64%)0.00020.989II38 (69.09%)53 (60.92%)0.9780.323III10 (18,18%)23 (26,44%)1.2870.257Duration (KOA, years (x ± s)9.71 ± 7.818.20 ± 6.591.2370.0218Combined underlying disease, n (%)11990.2740.0040.950Hypertension22 (40.00%)27 (31.03%)1.1990.024Hypertension22 (40.00%)25 (28.74%)0.0040.950Diables114 (25.45%)25 (28.74%)0.0450.502Coronary heart disease7 (12.73%)6 (6.90%)1.3780.241Chronic obstructive pulmonary11 (20.00%)11 (12.64%)0.0680.794Preoperative hemogloin, g/L (x ± s)132.55 ± 14.99132.93 ± 18.560.1280.809Anemia, n (%)3 (54.5%)3 (3.45%)0.6130.6230.808Operation ime, n (%)22 (21.8%)0.1190.2900.290Intrasperative hemorrhage, n (%)26 (29.89%)1.1190.290Intrasperative hemorrhage, n (%)21 (21.4%)0.6030.655200 mL11 (20.0%)21 (21.4%)0.6130.655200 mL0.110.2090.5160.555200 mL0.110.2900.5550.555200 mL0.110.2010.555200 mL0.110.2030.565200 mL0.110.20	Smoking, <i>n</i> (%)	13 (23.64%)	27 (31.03%)	0.912	0.340
I7 (12.73%)11 (12.64%)0.00020.989II38 (69.09%)53 (60.22%)0.0780.323III10 (18.18%)23 (26.44%)1.2870.257Duration of KOA, years (x ± s)9.71 ± 7.818.20 ± 6.591.2370.218Combined underlying diseases, n (%)77 (31.03%)1.1990.274Hypertension22 (40.00%)27 (31.03%)1.1990.0274Bypertension10 (18.18%)1.6 (18.39%)0.0040.959Diabetes14 (25.45%)2.5 (28.74%)0.4500.502Coronary heart disease5 (0.09%)11 (12.64%)0.6680.794Carebroxascular disease5 (0.09%)11 (12.64%)0.0680.794Chronic obstructive pulmonary11 (20.09%)11 (12.64%)0.0680.794Properative hemoglobin, gL (x ± s)132.55 ± 14.99132.93 ± 18.560.1280.689Anemia, n (%)3 (3.45%)0.0230.68800.794Coperative MMSE, scores (x ± s)27.84 ± 1.102.6 (29.89%)1.1190.290Lato in fine, n (%)2.6 (29.89%)1.1190.2900.6552.200 ml.14 (20.00%)2.6 (29.89%)1.1190.5652.200 ml.14 (20.00%)2.6 (29.89%)1.1190.5652.200 ml.14 (20.00%)2.6 (27.81%)0.6030.5652.200 ml.14 (20.00%)2.6 (27.81%)0.4030.5652.200 ml.14 (20.00%)16 (51.72%)0.4030.526Neutracial a	Drinking, n (%)	19 (34.55%)	30 (34.48%)	0.912	0.994
II138 (69.0%)53 (60.92%)0.9780.323III10 (18.18%)2.3 (26.44%)1.2870.257Daration of KOA, years (* ± s)9.71 ± 7.818.20 ± 6.591.2370.218Combined underlying diseases, n (%)1.1990.2740.274Hypertension2.2 (40.00%)2.7 (31.03%)1.1990.274Hypertension1.2 (40.00%)2.7 (31.03%)1.1990.0274Hypertension2.2 (40.00%)2.6 (28.74%)0.0040.950Diabetes1.4 (25.45%)2.5 (28.74%)0.04500.502Coronary heart disease7 (12.73%)6 (6.90%)1.3780.241Cerebrowacular disease5 (9.0%)111 (2.64%)0.0680.794Chronic obstructive pulmonary11 (25.514.9913.23 ± 18.560.1280.699Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Properative humoflage, ng (* ± s)12 (21.82%)3 (3.45%)0.1190.290210 min12 (21.82%)3 (1.61.119)0.2900.290Larone obstructive pulmonary14 (20.00%)2.6 (29.89%)1.1190.290210 min1.2 (21.82%)3 (1.61.71%)1.1190.290220 min4.4 (0.00%)2.6 (29.89%)1.1190.526200 min4.10 (20.0%)2.6 (29.89%)1.1190.526200 min4.10 (20.0%)2.6 (21.84%)0.0310.565200 min4.10 (20.0%)2.6 (21.84%)0.0310.526200 min9.9	ASA classification, <i>n</i> (%)				
III 10 (18.18%) 23 (26.4%) 1.287 0.257 Duration of KOA, years (x ± s) 9.71 ± 7.81 8.0 ± 6.59 1.237 0.218 Combined underlying diseases, n (%) 27 (31.03%) 1.199 0.274 Hyperlindemia 10 (18.18%) 16 (18.39%) 0.004 0.950 Diabetes 14 (25.45%) 25 (28.74%) 0.450 0.502 Coronary heart disease 7 (12.73%) 6 (6.90%) 1.378 0.241 Cerebrovascular disease 5 (9.09%) 111 (12.64%) 0.425 0.514 Chronic obstructive pulmonary 11 12.00%) 19 (21.84%) 0.068 0.794 Preoperative hemoglobin, g/L (x ± s) 3 (3.545%) 3 (3.45%) 0.023 0.880 Preoperative MIMSE, scores (x ± s) 27 (21.82%) 261 (29.89%) 1.119 0.290 2120 min 14 (20.09%) 21 (21.41%) 0.331 0.565 2200 mL 11 (20.00%) 21 (21.41%) 0.331 0.565 2200 mL 11 (20.00%) 21 (21.41%) 0.331 0.565	Ι	7 (12.73%)	11 (12.64%)	0.0002	0.989
Duration of KOA, years ($x \pm s$) $9,71 \pm 7.81$ 8.20 ± 6.59 1.237 0.218 Combined underlying diseases, n (%) 27 (31.03%) 1.199 0.274 Hypertension 22 (40.00%) 27 (31.03%) 1.199 0.274 Hyperlipidemia 10 (18.18%) 16 (18.39%) 0.004 0.950 Diabetes 14 (25.45%) 25 (28.74%) 0.450 0.502 Coronary heart disease 7 (12.73%) 6 (6.90%) 1.378 0.241 Cerebrovascular disease 5 (9.09%) 11 (12.64%) 0.425 0.514 Chronic obstructive pulmonary 11 (20.00%) 19 (21.84%) 0.028 0.794 Prooperative hemoglobin, g/L ($x \pm s$) 33.55 ± 14.99 33.235 ± 18.56 0.128 0.688 0.794 Prooperative hemoglobin, g/L ($x \pm s$) 33.55 ± 14.99 33.235 ± 18.56 0.023 0.880 Prooperative hemoglobin, g/L ($x \pm s$) 33.55 ± 14.99 23.03 ± 16.56 0.023 0.831 0.565 Quim ($x = 0.55 \pm 14.99$	II	38 (69.09%)	53 (60.92%)	0.978	0.323
Combined underlying diseases, n (%) Combined underlying diseases, n (%) I.199 0.274 Hypertinsion 22 (40.00%) 27 (31.03%) 1.199 0.274 Hyperlipidemia 10 (18.18%) 16 (18.39%) 0.004 0.950 Diabetes 14 (25.45%) 25 (28.74%) 0.450 0.502 Coronary heart disease 7 (12.73%) 6 (6.90%) 1.378 0.241 Cerebrovascular disease 5 (9.09%) 11 (12.64%) 0.425 0.514 Chronic obstructive pulmonary 111 (20.00%) 19 (21.84%) 0.068 0.794 Preoperative hemoglobin, g/L (*x ± s) 132.55 ± 14.99 132.93 ± 18.56 0.128 0.889 Anemia, n (%) 3 (3.45%) 0.023 0.880 0.794 Coperation time, n (%) 12 (21.82%) 26 (29.89%) 1.119 0.290 2120 min 12 (21.82%) 26 (29.89%) 1.119 0.290 Intraoperative hemorrhage, n (%) 31 (20.00%) 21 (24.14%) 0.331 0.565 ≥ 200 mL 11 (20.00%) 21 (24.14%)	III	10 (18.18%)	23 (26.44%)	1.287	0.257
Hypertension22 (40.00%)27 (31.03%)1.1990.274Hyperlipidenia10 (18.18%)16 (18.39%)0.0040.950Diabetes14 (25.45%)25 (28.74%)0.4500.502Coronary heart disease7 (12.73%)6 (6 60%)1.3780.241Cerebrovascular disease5 (9.09%)11 (12.64%)0.4250.514Chronic obstructive pulmonary11 (20.00%)19 (21.84%)0.0680.794Prooperative hemoglobin, g/L (*x ± s)132.55 ± 14.99132.93 ± 18.560.1280.889Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Prooperative MMSE, scores (*x ± s)27.84 ± 1.1028.10 ± 0.851.6240.107Operation time, n (%)11 (20.00%)26 (29.89%)1.1190.290 ≥ 120 min12 (21.82%)26 (29.89%)1.1190.290 ≥ 200 mL11 (20.00%)21 (24.14%)0.3310.565 ≥ 200 mL11 (20.00%)21 (24.14%)0.3310.565 ≥ 200 mL11 (20.00%)21 (24.14%)0.3310.565Anesthesia type, n (%)1410.2080.6110.023Muraxial anesthesia31 (56.36%)34 5(51.72%)0.4030.526Neuraxial anesthesia19 (34.55%)28 (32.18%)0.0850.711Combination anesthesia5 (9.09%)14 (16.09%)1.4250.233Anesthesia time, n (%)14.250.2330.661Anesthesia time, n (%)14 (2.59%)0.2730.601 <td>Duration of KOA, years ($^{-}x \pm s$)</td> <td>9.71 ± 7.81</td> <td>8.20 ± 6.59</td> <td>1.237</td> <td>0.218</td>	Duration of KOA, years ($^{-}x \pm s$)	9.71 ± 7.81	8.20 ± 6.59	1.237	0.218
Hyperhipidemia10 (18.18%)16 (18.39%)0.0040.950Diabetes14 (25.45%)25 (28.74%)0.4500.502Coronary heart disease7 (12.73%)6 (6.90%)1.3780.241Cerebrovascular disease5 (9.09%)11 (12.64%)0.4250.514Chronic obstructive pulmonary11 (20.00%)19 (21.84%)0.0680.794Preoperative hemoglobin, g/L (*x ± s)132.55 ± 14.99132.93 ± 18.560.1280.899Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Preoperative MMSE, scores (*x ± s)27.84 ± 1.1026 (29.89%)1.1190.29012 (21.82%)26 (29.89%)1.1190.290≥120 min11 (20.00%)21 (24.14%)0.3310.655≥200 mL41 (80.00%)66 (75.86%)0.3310.552Ansethesia type, n (%)11 (20.00%)21 (24.14%)0.4030.526Neartskia type, n (%)14 (60.0%)1.4250.2330.526Neartskia type, n (%)28 (32.18%)0.0850.7710.233Combination anesthesia31 (56.36%)28 (32.18%)0.0850.771Combination anesthesia5 (9.0%)14 (16.0%)1.4250.233Anesthesia time, n (%)14 (6.0%)1.4250.233Combination anesthesia5 (9.0%)14 (16.0%)1.4250.233Anesthesia time, n (%)13 (23.64%)24 (27.5%)0.0230.601	Combined underlying diseases, <i>n</i> (%)				
Dabets14 (25.45%)25 (28.74%)0.4500.502Coronary heart disease7 (12.73%)6 (6.90%)1.3780.241Cerebrovascular disease5 (9.09%)11 (12.64%)0.0680.794Chronic obstructive pulmonary11 (20.00%)19 (21.84%)0.0680.794Preoperative hemoglobin, g/L ($x \pm s$)132.55 ± 14.99132.93 ± 18.560.1280.889Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Preoperative MMSE, socres ($x \pm s$)27.84 ± 1.1028.10 ± 0.851.6240.107Operation time, n (%)12 (21.82%)26 (29.89%)1.1190.290 ≥ 120 min12 (21.82%)26 (29.89%)1.1190.290 ≥ 120 min11 (20.00%)21 (24.14%)0.3310.565 ≥ 200 mL11 (20.00%)21 (21.41%)0.3310.565 ≥ 200 mL11 (20.00%)21 (21.82%)0.4030.526 ≥ 200 mL11 (20.00%)21 (21.81%)0.0310.526 ≥ 200 mL11 (20.00%)21 (21.14%)0.3310.555 ≥ 200 mL31 (56.36%)45 (51.72%)0.4030.526Neurasia anesthesia31 (56.36%)28 (32.18%)0.0850.771General anesthesia5 (9.09%)14 (16.09%)1.4250.233Neurasia anesthesia5 (9.09%)28 (32.18%)0.0850.771Combination anesthesia5 (9.09%)14 (16.09%)1.4250.233Anesthesia time, n (%)1.4250.233	Hypertension	22 (40.00%)	27 (31.03%)	1.199	0.274
Coronary heart disease $7(12.73\%)$ $6(6.90\%)$ 1.378 0.241 Cerebrovascular disease $5(9.09\%)$ $11(12.64\%)$ 0.425 0.514 Chronic obstructive pulmonary $11(20.00\%)$ $19(21.84\%)$ 0.068 0.794 Preoperative hemoglobin, $g/L(^x \pm s)$ 132.55 ± 14.99 132.93 ± 18.56 0.128 0.899 Anemia, $n(\%)$ $3(5.45\%)$ $3(3.45\%)$ 0.023 0.880 Preoperative MMSE, scores ($^x \pm s$) 27.84 ± 1.10 28.10 ± 0.85 1.624 0.107 Operation time, $n(\%)$ $12(21.82\%)$ $26(29.89\%)$ 1.119 0.290 ≥ 120 min $12(21.82\%)$ $26(29.89\%)$ 1.119 0.290 ≥ 120 min $11(20.00\%)$ $21(24.14\%)$ 0.331 0.565 ≥ 200 mL $44(80.00\%)$ $66(75.86\%)$ 0.331 0.565 ≥ 200 mL $31(56.36\%)$ $45(51.72\%)$ 0.403 0.526 Neuraxial anesthesia $31(56.36\%)$ $28(32.18\%)$ 0.085 0.771 General anesthesia $5(9.09\%)$ $14(16.09\%)$ 1.425 0.233 Anesthesia time, $n(\%)$ $14(16.09\%)$ 1.425 0.233 Anesthesia time, $n(\%)$ $5(9.09\%)$ $14(16.09\%)$ 0.273 0.601	Hyperlipidemia	10 (18.18%)	16 (18.39%)	0.004	0.950
Cerebroxacular disease $5(9.09\%)$ $11(12.64\%)$ 0.425 0.514 Chronic obstructive pulmonary $11(20.00\%)$ $19(21.84\%)$ 0.068 0.794 Preoperative hemoglobin, g/L ("x ± s) 132.55 ± 14.99 132.93 ± 18.56 0.128 0.899 Anemia, n (%) $3(5.45\%)$ $3(3.45\%)$ 0.023 0.880 Preoperative MMSE, scores ("x ± s) 27.84 ± 1.10 28.10 ± 0.85 1.624 0.107 Operation time, n (%) $12(21.82\%)$ $26(29.89\%)$ 1.119 0.290 ≥ 120 min $12(21.82\%)$ $26(29.89\%)$ 1.119 0.290 ≥ 120 min $11(20.00\%)$ $21(24.14\%)$ 0.331 0.565 ≥ 200 mL $11(20.00\%)$ $21(24.14\%)$ 0.331 0.565 ≥ 200 mL $44(80.00\%)$ $66(75.86\%)$ 0.331 0.526 Anesthesia type, n (%) $19(34.55\%)$ $28(32.18\%)$ 0.043 0.526 Neuraxial anesthesia $31(56.36\%)$ $14(16.09\%)$ 1.425 0.233 Anesthesia time, n (%) $14(16.09\%)$ 1.425 0.233	Diabetes	14 (25.45%)	25 (28.74%)	0.450	0.502
Chronic obstructive pulmonary11 (20.00%)19 (21.84%)0.0680.794Preoperative hemoglobin, g/L ("x ± s)132.55 ± 14.99132.93 ± 18.560.1280.899Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Preoperative MMSE, scores ("x ± s)27.84 ± 1.1028.10 ± 0.851.6240.107Operation time, n (%)12 (21.82%)26 (29.89%)1.1190.290 ≥ 120 min12 (21.82%)26 (29.89%)1.1190.290 ≥ 120 min43 (78.18%)61 (70.11%)1.1190.290Intraoperative hemorrhage, n (%)21 (24.14%)0.3310.565 ≥ 200 mL41 (80.00%)66 (75.86%)0.3310.565 ≥ 200 mL31 (56.36%)45 (51.72%)0.4030.526Neuraxial anesthesia31 (56.36%)28 (32.18%)0.0850.771Combination anesthesia5 (9.09%)14 (16.09%)1.4250.233Anesthesia time, n (%)24 (27.59%)0.0250.601	Coronary heart disease	7 (12.73%)	6 (6.90%)	1.378	0.241
Preoperative hemoglobin, g/L (`x ± s)132.55 ± 14.99132.93 ± 18.560.1280.899Anemia, n (%)3 (5.45%)3 (3.45%)0.0230.880Preoperative MMSE, scores (`x ± s)27.84 ± 1.1028.10 ± 0.851.6240.107Operation time, n (%)2120 min12 (21.82%)26 (29.89%)1.1190.290≥120 min12 (21.82%)61 (70.11%)1.1190.290≥120 min43 (78.18%)61 (70.11%)1.1190.290Intraoperative hemorrhage, n (%)21 (24.14%)0.3310.565≥00 mL44 (80.00%)66 (75.86%)0.3310.565≥00 mL31 (56.36%)45 (51.72%)0.4030.526Neuraxial anesthesia31 (56.36%)28 (32.18%)0.0850.771Combination anesthesia5 (9.09%)14 (16.09%)1.4250.233Anesthesia time, n (%)21 (24.75%)0.0250.601	Cerebrovascular disease	5 (9.09%)	11 (12.64%)	0.425	0.514
Anemia, n (%) 3 (5.45%) 3 (3.45%) 0.023 0.880 Preoperative MMSE, scores (*x ± s) 27.84 ± 1.10 28.10 ± 0.85 1.624 0.107 Operation time, n (%)<120 min	Chronic obstructive pulmonary	11 (20.00%)	19 (21.84%)	0.068	0.794
Preoperative MMSE, scores (`x ± s) 27.84 ± 1.10 28.10 ± 0.85 1.624 0.107 Operation time, n (%)<120 min	Preoperative hemoglobin, g/L (⁻ x \pm s)	132.55 ± 14.99	132.93 ± 18.56	0.128	0.899
Operation time, n (%) Operation time, n (%) Image: 12 (21.82%) 26 (29.89%) 1.119 0.290 ≥ 120 min 12 (21.82%) 61 (70.11%) 1.119 0.290 ≥ 120 min 43 (78.18%) 61 (70.11%) 1.119 0.290 Intraoperative hemorrhage, n (%) 21 (24.14%) 0.331 0.565 ≥ 200 mL 11 (20.00%) 21 (24.14%) 0.331 0.565 ≥ 200 mL 44 (80.00%) 66 (75.86%) 0.331 0.565 Anesthesia type, n (%) 9 9 9 9 9 General anesthesia 31 (56.36%) 45 (51.72%) 0.403 0.526 Neuraxial anesthesia 19 (34.55%) 28 (32.18%) 0.085 0.771 Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 113 (23.64%) 24 (27.59%) 0.273 0.601	Anemia, <i>n</i> (%)	3 (5.45%)	3 (3.45%)	0.023	0.880
12 (21.82%) 26 (29.89%) 1.119 0.290 ≥120 min 43 (78.18%) 61 (70.11%) 1.119 0.290 Intraoperative hemorrhage, n (%) 21 (24.14%) 0.331 0.565 ≥200 mL 11 (20.00%) 21 (24.14%) 0.331 0.565 ≥200 mL 44 (80.00%) 66 (75.86%) 0.331 0.565 ≥200 mL 44 (80.00%) 66 (75.86%) 0.331 0.565 Anesthesia type, n (%) 91 91 (94.55%) 92 (92.18%) 0.085 0.771 General anesthesia 31 (56.36%) 14 (16.09%) 1.425 0.233 Neuraxial anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 91 (93.64%) 24 (27.59%) 0.273 0.601	Preoperative MMSE, scores (⁻ x ± s)	27.84 ± 1.10	28.10 ± 0.85	1.624	0.107
≥120 min $43 (78.18\%)$ $61 (70.11\%)$ 1.119 0.290 Intraoperative hemorrhage, n (%)<200 mL	Operation time, <i>n</i> (%)			1	
Intraoperative hemorrhage, n (%) Intraoperative hemorrhage, n (%) Intraoperative hemorrhage, n (%) 21 (24.14%) 0.331 0.565 ≥200 mL 44 (80.00%) 66 (75.86%) 0.331 0.565 Anesthesia type, n (%) 66 (75.86%) 0.331 0.565 Neuraxial anesthesia 31 (56.36%) 45 (51.72%) 0.403 0.526 Neuraxial anesthesia 19 (34.55%) 28 (32.18%) 0.085 0.771 Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 24 (27.59%) 0.273 0.601	<120 min	12 (21.82%)	26 (29.89%)	1.119	0.290
	≥120 min	43 (78.18%)	61 (70.11%)	1.119	0.290
≥200 mL 44 (80.00%) 66 (75.86%) 0.331 0.565 Anesthesia type, n (%) <t< td=""><td>Intraoperative hemorrhage, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></t<>	Intraoperative hemorrhage, <i>n</i> (%)				
Anesthesia type, n (%) Affect (%) Anesthesia (%) General anesthesia 31 (56.36%) 45 (51.72%) 0.403 0.526 Neuraxial anesthesia 19 (34.55%) 28 (32.18%) 0.085 0.771 Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 24 (27.59%) 0.273 0.601	<200 mL	11 (20.00%)	21 (24.14%)	0.331	0.565
General anesthesia 31 (56.36%) 45 (51.72%) 0.403 0.526 Neuraxial anesthesia 19 (34.55%) 28 (32.18%) 0.085 0.771 Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 24 (27.59%) 0.273 0.601	≥200 mL	44 (80.00%)	66 (75.86%)	0.331	0.565
Neuraxial anesthesia 19 (34.55%) 28 (32.18%) 0.085 0.771 Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%) 24 (27.59%) 0.273 0.601	Anesthesia type, <i>n</i> (%)				
Combination anesthesia 5 (9.09%) 14 (16.09%) 1.425 0.233 Anesthesia time, n (%)	General anesthesia	31 (56.36%)	45 (51.72%)	0.403	0.526
Anesthesia time, n (%) 24 (27.59%) 0.273 0.601	Neuraxial anesthesia	19 (34.55%)	28 (32.18%)	0.085	0.771
<150 min 13 (23.64%) 24 (27.59%) 0.273 0.601	Combination anesthesia	5 (9.09%)	14 (16.09%)	1.425	0.233
	Anesthesia time, n (%)				
≥150 min 42 (76.36%) 63 (72.41%) 0.273 0.601	<150 min	13 (23.64%)	24 (27.59%)	0.273	0.601
	≥150 min	42 (76.36%)	63 (72.41%)	0.273	0.601

CS, central sensitization; BMI, body mass index; ASA, American society of anesthesiologists; KOA, knee osteoarthritis; MMSE, Mini-Mental State Examination.

3.5 Univariate and multivariate logistic regression analysis of postoperative POCD occurrence

The univariate logistic regression identified significant associations between POCD and CSI score, coronary heart disease, cerebrovascular disease, preoperative MMSE scores, intraoperative hemorrhage, and anesthesia time (all p < 0.05). To further evaluate the independent impact of central sensitization (CSI score) on the incidence of POCD, a multivariate logistic regression model was constructed. The analysis revealed that a CSI score of \geq 40 (OR = 4.05, 95% CI = 1.52–11.54, p = 0.006), cerebrovascular disease (OR = 4.33, 95% CI = 1.09–18.68, p = 0.026), preoperative MMSE score < 27 (OR = 1.81, 95% CI = 1.04–3.26, p = 0.045), and intraoperative hemorrhage \geq 200 mL (OR = 5.07,



TABLE 2 Comparison of MMSE scores between two groups.

	то	Т2	Т3	T4	Т5
MMSE score					
CS	27.84 ± 1.10	26.44 ± 0.86	27.85 ± 1.11	26.49 ± 0.90	27.24 ± 0.78
NCS	28.10 ± 0.85	27.25 ± 0.78	28.08 ± 0.85	27.24 ± 0.78	28.08 ± 0.84
t^a , p value ^{a}	1.624, 0.107	5.848, < 0.001	5.131, < 0.001	4.029, < 0.001	4.365, < 0.001
$t^{\rm b}$, p value ^b		7.903, < 0.001	7.275, < 0.001	1.937, 0.058	1.552, 0.126
t^{c} , p value ^c		8.608, < 0.001	9.061, < 0.001	0.591, 0.556	0.910, 0.365

Bold indicates statistical significance p < 0.05.

T0, preoperatively; T2, postoperative day 1; T3, postoperative day 3; T4, postoperative day 7; T5, postoperative day 30; MMSE, Mini-Mental State Examination; CS, central sensitization. ^aStatistical comparison between groups at each time point (Independent samples t-tests).

^bStatistical comparison of different time points with the T0 time point in the CS group (Paired t-tests).

'Statistical comparison of different time points with the T0 time point in the Non-CS group (Paired t-tests).



95% CI = 1.58–20.14, p = 0.011) were significantly associated with a higher risk of POCD in TKA patients after adjusting for confounding factors (Table 4).

4 Discussion

This study demonstrates that CS is a significant risk factor for POCD following TKA. A retrospective analysis of 142 patients revealed that 30.91% of the CS group experienced POCD, compared to 12.64% in the non-CS group. Additionally, the CS group exhibited lower MMSE scores at multiple postoperative time points, along with lower pain and quality of life scores in the KOOS subdomains compared to the non-sensitized group. Logistic regression analysis further indicated that even after accounting for potential confounders, a higher CSI score (\geq 40) remained an independent risk factor for POCD. This finding clearly underscores the critical role of CS in impairing neurocognitive recovery following TKA.

TABLE 3 Comparison of KOOS scores between two groups.

	Т0	T2	Т3	T4	Т5
KOOS Pain					
CS	47.24 ± 7.36	33.65 ± 5.89	38.07 ± 5.94	39.93 ± 6.50	51.18 ± 7.47
NCS	51.30 ± 7.82	35.62 ± 6.33	40.10 ± 6.53	46.18 ± 6.63	60.98 ± 6.83
<i>t</i> ^{<i>a</i>} , <i>p</i> value ^{<i>a</i>}	3.085, 0.002	1.852, 0.067	1.868, 0.064	5.522, < 0.001	8.029, < 0.001
$t^{\rm b}$, p value ^b		12.51, < 0.001	7.811, < 0.001	5.702, < 0.001	2.691, 0.010
ť, p value ^c		17.80, < 0.001	10.62, < 0.001	4.478, < 0.001	9.420, < 0.001
KOOS Symptoms					
CS	51.47 ± 7.16	37.56 ± 5.40	41.33 ± 5.99	44.82 ± 5.78	66.96 ± 5.39
NCS	51.23 ± 6.97	38.78 ± 5.66	42.54 ± 5.64	45.61 ± 5.45	68.60 ± 7.35
<i>t</i> ^{<i>a</i>} , <i>p</i> value ^{<i>a</i>}	0.200, 0.842	1.272, 0.206	1.218, 0.225	0.823, 0.412	1.423, 0.157
$t^{\rm b}$, p value ^b		13.07, < 0.001	7.842, < 0.001	5.444, < 0.001	12.19, < 0.001
t ^c , p value ^c		17.83, < 0.001	8.934, < 0.001	5.793, < 0.001	15.34, < 0.001
KOOS ADL					
CS	42.43 ± 7.46	31.42 ± 4.39	33.55 ± 5.14	36.18 ± 5.92	62.91 ± 8.08
NCS	43.78 ± 7.27	31.97 ± 4.83	32.46 ± 5.33	37.36 ± 5.33	65.10 ± 5.60
t ^a , p value ^a	1.067,0.288	0.681, 0.497	1.205, 0.230	1.231, 0.220	1.907, 0.059
$t^{\rm b}$, p value ^b		10.24, < 0.001	7.808, < 0.001	5.223, < 0.001	13.74, < 0.001
t ^c , p value ^c		14.38, < 0.001	11.58, < 0.001	6.756, < 0.001	22.29, < 0.001
KOOS Sport/Rec					
CS	18.11 ± 4.54	12.01 ± 3.29	13.77 ± 2.97	19.43 ± 3.38	38.13 ± 4.31
NCS	17.98 ± 4.13	12.91 ± 3.08	14.45 ± 3.70	19.30 ± 4.43	38.21 ± 4.89
t ^a , p value ^a	0.183, 0.855	1.646,0.102	1.146, 0.254	0.180, 0.858	0.103, 0.918
t ^b , p value ^b		8.021, < 0.001	5.744, < 0.001	2.117, 0.039	22.79, < 0.001
t ^c , p value ^c		10.46, < 0.001	6.557, < 0.001	2.180, 0.032	23.56, < 0.001
KOOS QoL					
CS	19.63 ± 5.95	19.05 ± 6.28	32.36 ± 6.12	37.89 ± 6.42	47.27 ± 6.18
NCS	23.35 ± 5.50	20.72 ± 5.26	33.81 ± 5.94	42.04 ± 6.80	47.27 ± 6.18
t ^a , p value ^a	2.713, 0.008	1.188, 0.237	1.404, 0.163	3.619, < 0.001	9.644, < 0.001
$t^{\rm b}$, p value ^b		2.571, 0.013	11.83, < 0.001	16.67, < 0.001	21.60, < 0.001
t^{c} , p value ^c		6.044, < 0.001	11.82, < 0.001	20.91, < 0.001	35.42, < 0.001

Bold indicates statistical significance p < 0.05.

T0, preoperatively; T2, postoperative day 1; T3, postoperative day 3; T4, postoperative day 7; T5, postoperative day 30; CS, central sensitization; KOOS, Knee Injury and Osteoarthritis Outcome Score; Rec, Recreation; ADL, activity of daily living; QoL, quality of life.

^aStatistical comparison between groups at each time point (Independent samples t-tests).

^bStatistical comparison of different time points with the T0 time point in the CS group (Paired t-tests).

Statistical comparison of different time points with the T0 time point in the Non-CS group (Paired t-tests).

TKA is one of the most cost-effective surgeries in orthopedics. Despite its high success rate, postoperative complications, especially POCD, are increasingly concerning, with rates reported to range from 19.4 to 72.0% 1 week postoperatively (4). Although the precise mechanisms underlying POCD remain unclear, several risk factors are known to be closely associated, including lower educational level (29), older age (30), alcohol use disorder (31, 32), preexisting cognitive impairment (33, 34). This study is the first to reveal a close link between CS and POCD, suggesting that CS not only affects postoperative pain management but may also exacerbate cognitive decline following TKA.

CS refers to a persistent and exaggerated response of the central nervous system to painful stimuli, characterized by a lowered pain

threshold and abnormal pain perception. Recent studies have demonstrated that CS not only alters pain perception but may also impair cognitive function through various mechanisms (10). Neuroinflammation is considered a key pathophysiological foundation of CS. In chronic pain conditions, pro-inflammatory signals released from peripheral tissues can penetrate the blood-brain barrier, activating microglia and astrocytes, which in turn heightens neuronal excitability, leading to neuronal damage and apoptosis, potentially affecting cognitive function (35, 36). TKA is a highly invasive procedure often accompanied by severe postoperative pain and inflammation. During this process, the release of pro-inflammatory cytokines, such as IL-6, TNF- α , and IL-1 β , exacerbates the effects of CS, potentially contributing to the development of POCD (37, 38).



This mechanism may explain the occurrence of POCD in TKA patients, and the impact is likely to be more pronounced in those with CS. The results of this study's MMSE assessments further support this hypothesis, indicating that CS may negatively affect postoperative cognitive recovery through similar mechanisms. We observed significant declines in MMSE scores on postoperative days 1and 3 compared to preoperative scores in both the CS and control groups, suggesting marked cognitive deterioration in the acute phase of TKA, which aligns with previous research. Additionally, MMSE scores in the CS group were significantly lower than those in the control group on postoperative days 1, 3, and 7, indicating a notable delay in cognitive recovery during the acute postoperative period among CS patients. This trend persisted through postoperative day 30, suggesting that CS has a sustained negative impact on long-term cognitive recovery. However, the potential impact of the learning effect could not be ignored. Conducting the MMSE assessment five times within 1 month might have led to patients becoming familiar with the test, artificially improving scores without truly reflecting cognitive recovery. Although we implemented standardized testing procedures and multidimensional data analyses to minimize the learning effect, it is not entirely possible to rule out its influence on the results. Furthermore, as this is a retrospective study, we were unable to directly verify or quantify the existence of the learning effect through experimental design. Future research should consider longer intervals between assessments or incorporate more complex cognitive tests to reduce the impact of the learning effect.

The KOOS results further demonstrated the negative impact of CS on postoperative recovery following TKA. Repeated measures ANOVA revealed that the CS group had significantly lower pain and quality of life scores compared to the non-sensitized group, while no significant differences were observed in the subdomains of symptoms, daily living activities, or sports/recreation. This suggests that CS primarily affects pain perception and quality of life, rather than other functional domains of the knee. Moreover, time had a significant main effect across all KOOS subdomains, indicating that overall knee function improved postoperatively for all patients. However, the interaction between time and group was significant for pain and quality of life scores, indicating that the trajectories of postoperative pain relief and quality of life recovery differed significantly between the high-sensitization and low-sensitization groups. Notably, by postoperative days 7 and 30, the CS group showed a marked delay in pain perception relief and quality of life improvement. This suggests that CS not only exacerbates postoperative pain perception but may also hinder the recovery of knee function by affecting patients' psychological states and fear of physical activity, thereby exerting a prolonged negative effect on long-term quality of life. Consequently, during postoperative recovery in CS patients, greater emphasis should be placed on pain management and quality of life enhancement.

Notably, in the univariate and multivariate logistic regression analyses, even after adjusting for multiple confounding factors, central sensitization (CSI score ≥ 40) was identified as a significant risk factor for POCD following TKA, further emphasizing the critical role of CS in the development of POCD. Additionally, patients with cerebrovascular disease, intraoperative hemorrhage exceeding 200 mL and preoperative MMSE scores below 27 were significantly associated with an increased risk of POCD, suggesting that underlying cerebrovascular conditions, physiological stressors (such as intraoperative blood loss) and baseline cognitive function are key contributors to the occurrence of POCD. Consistent with previous research (2, 39), we speculate that patients with central sensitization may experience a heightened stress response during surgery, potentially leading to increased blood loss and a compounded neurocognitive burden. This finding also underscores the necessity of a thorough preoperative assessment, including screening for cognitive impairment, and cerebrovascular health, as well as meticulous intraoperative management for

TABLE 4 Univariate and multivariate logistic regression of postoperative POCD occurrence.

Variables	Univariate log	gistic regression	Multivariate logi	Multivariate logistic regression		
	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value		
$CSI \ge 40$	3.09 (1.33-7.43)	0.010	4.05 (1.52–11.54)	0.006		
Age	1.03 (0.95-1.12)	0.461				
Gender	0.84 (0.36-1.92)	0.673				
BMI	0.99 (0.89-1.10)	0.848				
Educational level below high school	0.41 (0.15–1.00)	0.062				
ASA classification						
I	0.47 (0.07-1.80)	0.336				
II	1.23 (0.52-3.09)	0.643				
III	1.13 (0.41-2.85)	0.806				
Smoking	1.90 (0.45-2.44)	0.149				
Drinking	0.45 (0.16-1.14)	0.110				
Duration of KOA	1.04 (0.99–1.10)	0.130				
Combined underlying diseases						
Hypertension	1.29 (0.54-3.01)	0.553				
Hyperlipidemia	0.48 (0.11-1.51)	0.255				
Diabetes	1.63 (0.66–3.88)	0.278				
Coronary heart disease	4.17 (1.27–13.77)	0.018	2.49 (0.58-10.92)	0.216		
Cerebrovascular disease	3.89 (1.27-11.64)	0.015	4.33 (1.09–18.68)	0.026		
Chronic obstructive pulmonary	2.10 (0.81-5.21)	0.116				
Preoperative hemoglobin	1.02 (0.99–1.05)	0.139				
Anemia	0.81 (0.04-5.28)	0.848				
Preoperative MMSE scores <27	2.28 (1.40-3.93)	0.002	1.81 (1.04–3.26)	0.045		
Operation time \geq 120 min	1.60 (0.55–5.83)	0.423				
Intraoperative hemorrhage≥200 mL	10.08 (2.01–183.6)	0.026	10.51 (1.79–208.3)	0.040		
Anesthesia type						
General anesthesia	1.74 (0.75-4.22)	0.206				
Neuraxial anesthesia	0.37 (0.12-0.98)	0.063				
Combination anesthesia	1.55 (0.46-4.53)	0.440				
Anesthesia time \geq 150 min	6.00 (1.67-38.49)	0.019	1.77 (1.03-33.20)	0.077		

Bold indicates statistical significance p < 0.05.

CSI, central sensitization inventory; BMI, body mass index; ASA, American society of anesthesiologists; KOA, knee osteoarthritis; MMSE, Mini-Mental State Examination.

patients at risk of central sensitization to mitigate these adverse outcomes.

Although this study provides new evidence for understanding the association between CS and POCD, several limitations should be acknowledged. First, as a retrospective study, this research can only reveal correlations between patients with more pronounced CS symptoms and POCD, without establishing causality. Second, although multiple potential confounding factors were adjusted for, other factors not accounted for in the study-such as postoperative infections, preoperative and intraoperative drug use, emotional disorders like depression and anxiety, and sleep disturbances-may also influence the occurrence of POCD. Third, conducting the MMSE assessment five times within 1 month may have introduced a learning effect, where patients' familiarity with the test could artificially improve scores rather than reflect true cognitive recovery. Moreover, the MMSE may lack the sensitivity required to identify nuanced cognitive changes, potentially affecting the accuracy of POCD evaluation. Future studies should consider adopting more detailed neuropsychological assessment tools to comprehensively evaluate specific cognitive domains. Fourth, the sample size of this study was relatively small, and the follow-up points were limited to postoperative days 1, 3, 7, and 30. The short follow-up duration and small sample size may introduce bias, and the findings should therefore be interpreted with caution. Finally, the study did not utilize imaging

techniques, such as structural MRI, FDG-PET, or resting-state fMRI, nor were biomarkers employed to explore the impact of CS on patients (40). This limits the understanding of the neural mechanisms underlying POCD and hinders the development of personalized treatment strategies.

5 Conclusion

This study suggests that CS may be a novel risk factor for POCD following TKA, and may adversely affect postoperative recovery in terms of cognitive function, pain, and quality of life. Preoperative assessment of CS, particularly through individualized management of patients with chronic pain, may help reduce the incidence of POCD and improve overall postoperative outcomes after TKA. Future prospective, multicenter studies are needed to validate these findings and explore additional interventions to mitigate the negative impact of CS on postoperative cognitive function.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the Second Affiliated Hospital of Anhui University of Chinese Medicine (Approval number: 2023-zj-40). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin due to the retrospective nature of the study.

Author contributions

QY: Conceptualization, Data curation, Writing - original draft, Writing – review & editing. CL: Data curation, Formal analysis, Validation, Writing – original draft, Writing – review & editing. MY: Conceptualization, Formal analysis, Software, Writing – original draft.

References

1. Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. *JAMA*. (2012) 308:1227–36. doi: 10.1001/2012.jama.11153

2. Zhao Y, Zang C, Ren S, Fu J, Liu N, Zhou Z, et al. Effects of different levels of controlled hypotension on regional cerebral oxygen saturation and postoperative cognitive function in patients undergoing total knee arthroplasty. *Front Med (Lausanne).* (2022) 9:989341. doi: 10.3389/fmed.2022.989341

3. Liu K, Liu Y, Ma X, Fu D, Fan Z. Effect of cognitive behavioral therapy on pain, knee function, and psychological status in patients after primary total knee arthroplasty: a systematic review and meta-analysis. *BMC Musculoskelet Disord*. (2024) 25:280. doi: 10.1186/s12891-024-07413-1

XZ: Data curation, Validation, Writing – original draft. WL: Data curation, Validation, Writing – review & editing. FL: Conceptualization, Funding acquisition, Supervision, Visualization, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is supported by the National Youth Qihuang Scholar Cultivation Program of National Administration of Traditional Chinese Medicine [Document No. 256 (2022)], the Natural Science Foundation of Anhui Province (No.2308085MH297), and the Natural Science Research Project Funding of Higher Education Institutions of Anhui Province (Nos. 2023AH040099, KJ2021A0549).

Acknowledgments

We sincerely thank all the participants of this study for their invaluable contributions to its completion.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

4. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, et al. Predictors of cognitive dysfunction after major noncardiac surgery. *Anesthesiology*. (2008) 108:18–30. doi: 10.1097/01.anes.0000296071.19434.1e

5. Hu XC, Yang XM, Li L, Yu J, Si XB, Niu ZQ. Effects of dexmedetomidine on renal function, inflammatory markers, and cognitive functioning in elderly patients undergoing hip replacement surgery. *Am J Transl Res.* (2024) 16:3713–22. doi: 10.62347/ YFAI7091

^{6.} Kitsis P, Zisimou T, Gkiatas I, Kostas-Agnantis I, Gelalis I, Korompilias A, et al. Postoperative delirium and postoperative cognitive dysfunction in patients with elective hip or knee arthroplasty: a narrative review of the literature. *Life (Basel)*. (2022) 12:314. doi: 10.3390/life12020314

7. Zhao Q, Wan H, Pan H, Xu Y. Postoperative cognitive dysfunction-current research progress. *Front Behav Neurosci.* (2024) 18:1328790. doi: 10.3389/fnbeh.2024.1328790

8. Subramaniyan S, Terrando N. Neuroinflammation and perioperative neurocognitive disorders. *Anesth Analg.* (2019) 128:781-8. doi: 10.1213/ANE. 000000000004053

9. Huang J, Bin ARH, Yeo SJ. Incidence of postoperative delirium in patients undergoing total knee arthroplasty-an Asian perspective. *Ann Transl Med.* (2017) 5:321. doi: 10.21037/atm.2017.06.40

10. Yu L, Yang D, Zhou Q, Yin C, Zhang Q, Li W, et al. The effect of central sensitization on postoperative neurocognitive dysfunction in hospitalized elderly patients: a prospective cohort clinical trial. *Exp Aging Res.* (2024) 50:155–70. doi: 10.1080/0361073X.2023.2182093

11. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*. (2011) 152:S2–S15. doi: 10.1016/j.pain.2010.09.030

12. Sasaki E, Kasai T, Araki R, Sasaki T, Wakai Y, Akaishi K, et al. Central sensitization and postoperative improvement of quality of life in Total knee and Total hip arthroplasty: a prospective observational study. *Prog Rehabil Med.* (2022) 7:20220009. doi: 10.2490/ prm.20220009

13. Kim MS, Koh IJ, Sohn S, Kang BM, Kwak DH, In Y. Central sensitization is a risk factor for persistent postoperative pain and dissatisfaction in patients undergoing revision Total knee arthroplasty. *J Arthroplast.* (2019) 34:1740–8. doi: 10.1016/j. arth.2019.03.042

14. Vervullens S, Meert L, Smeets R, Verbrugghe J, Verdonk P, Meeus M. Does pain intensity after total knee arthroplasty depend on somatosensory functioning in knee osteoarthritis patients? A prospective cohort study. *Clin Rheumatol.* (2024) 43:2047–59. doi: 10.1007/s10067-024-06976-7

15. Rajani AM, Mittal A, Kulkarni VU, Desai MK, Dubey RR, Rajani KA, et al. Duloxetine as an analgesic in patients who do not have central sensitivity undergoing single-setting, bilateral Total knee arthroplasty: a prospective, double-blinded, randomized, Placebo-Controlled Trial. *J Arthroplasty.* (2024) 39:2055–60. doi: 10.1016/j. arth.2024.02.007

16. Zhou M, Pang F, Liao D, Yang Y, Wang Y, Yang Z, et al. Electroacupuncture improves allodynia and central sensitization via modulation of microglial activation associated P2X4R and inflammation in a rat model of migraine. *Mol Pain.* (2024) 20:824459393. doi: 10.1177/17448069241258113

17. Puts S, Njemini R, Bilterys T, Lefeber N, Scheerlinck T, Nijs J, et al. Linking intraarticular inflammatory biomarkers with peripheral and central sensitization in late-stage knee osteoarthritis pain: a pilot study. *J Clin Med.* (2024) 13:13. doi: 10.3390/jcm13175212

18. Mokhtari T, Irandoost E, Sheikhbahaei F. Stress, pain, anxiety, and depression in endometriosis-targeting glial activation and inflammation. *Int Immunopharmacol.* (2024) 132:111942. doi: 10.1016/j.intimp.2024.111942

19. Niu J, Li Y, Zhou Q, Liu X, Yu P, Gao F, et al. The association between physical activity and delayed neurocognitive recovery in elderly patients: a mediation analysis of pro-inflammatory cytokines. *Aging Clin Exp Res.* (2024) 36:192. doi: 10.1007/s40520-024-02846-z

20. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology*. (2018) 129:343–66. doi: 10.1097/ALN.00000000002130

21. Campbell CM, Buenaver LF, Finan P, Bounds SC, Redding M, McCauley L, et al. Sleep, pain catastrophizing, and central sensitization in knee osteoarthritis patients with and without insomnia. *Arthritis Care Res (Hoboken)*. (2015) 67:1387–96. doi: 10.1002/acr.22609

22. Martin JR, Coronado RA, Wilson JM, Polkowski GG, Shinar AA, Bruehl SP. Central sensitization: the missing link between psychological distress and poor outcome following primary Total knee arthroplasty. *J Arthroplast.* (2024) 39:1201–6. doi: 10.1016/j.arth.2023.12.026

23. Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the central sensitization inventory: a systematic review. *Pain Pract.* (2018) 18:544–54. doi: 10.1111/papr.12636

24. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the central sensitization inventory. *Pain Pract.* (2017) 17:166–75. doi: 10.1111/papr.12440

25. Kaya MN, Tecer D, Kilic O, Ozgunen MS, Yilmaz S. Impact of central sensitization on clinical and functional aspects of psoriatic arthritis. *Medicina (Kaunas)*. (2024) 60:60. doi: 10.3390/medicina60091449

26. Katzman R, Zhang MY, Qu O-Y, Wang ZY, Liu WT, Yu E, et al. A Chinese version of the Mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. *J Clin Epidemiol.* (1988) 41:971–8. doi: 10.1016/0895-4356(88)90034-0

27. Evered L, Silbert B, Knopman DS, Scott DA, DeKosky ST, Rasmussen LS, et al. Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery-2018. *Br J Anaesth*. (2018) 121:1005–12. doi: 10.1016/j.bja.2017.11.087

28. Silva A, Croci AT, Gobbi RG, Hinckel BB, Pecora JR, Demange MK. Translation and validation of the new version of the knee society score - the 2011 KS score - into Brazilian Portuguese. *Rev Bras Ortop.* (2017) 52:506–10. doi: 10.1016/j. rbo.2016.08.005

29. Feinkohl I, Winterer G, Spies CD, Pischon T. Cognitive reserve and the risk of postoperative cognitive dysfunction. *Dtsch Arztebl Int*. (2017) 114:110–7. doi: 10.3238/arztebl.2017.0110

30. O'Gara BP, Mueller A, Gasangwa D, Patxot M, Shaefi S, Khabbaz K, et al. Prevention of early postoperative decline: a randomized, controlled feasibility trial of perioperative cognitive training. *Anesth Analg.* (2020) 130:586–95. doi: 10.1213/ ANE.000000000004469

31. Hudetz JA, Iqbal Z, Gandhi SD, Patterson KM, Hyde TF, Reddy DM, et al. Postoperative cognitive dysfunction in older patients with a history of alcohol abuse. *Anesthesiology.* (2007) 106:423–30. doi: 10.1097/00000542-200703000-00005

32. Hudetz JA, Patterson KM, Byrne AJ, Iqbal Z, Gandhi SD, Warltier DC, et al. A history of alcohol dependence increases the incidence and severity of postoperative cognitive dysfunction in cardiac surgical patients. *Int J Environ Res Public Health.* (2009) 6:2725–39. doi: 10.3390/ijerph6112725

33. Silbert B, Evered L, Scott DA, McMahon S, Choong P, Ames D, et al. Preexisting cognitive impairment is associated with postoperative cognitive dysfunction after hip joint replacement surgery. *Anesthesiology.* (2015) 122:1224–34. doi: 10.1097/ALN.00000000000671

34. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. *Arch Neurol.* (2009) 66:1151–7. doi: 10.1001/archneurol.2009.106

35. Jang JH, Kim YK, Jung WM, Kim HK, Song EM, Kim HY, et al. Acupuncture improves comorbid cognitive impairments induced by neuropathic pain in mice. *Front Neurosci.* (2019) 13:995. doi: 10.3389/fnins.2019.00995

36. Liu Y, Zhou LJ, Wang J, Li D, Ren WJ, Peng J, et al. TNF-alpha differentially regulates synaptic plasticity in the Hippocampus and spinal cord by microgliadependent mechanisms after peripheral nerve injury. *J Neurosci.* (2017) 37:871–81. doi: 10.1523/JNEUROSCI.2235-16.2016

37. Awada HN, Luna IE, Kehlet H, Wede HR, Hoevsgaard SJ, Aasvang EK. Postoperative cognitive dysfunction is rare after fast-track hip- and knee arthroplasty - but potentially related to opioid use. *J Clin Anesth.* (2019) 57:80–6. doi: 10.1016/j. jclinane.2019.03.021

38. Scott JE, Mathias JL, Kneebone AC. Postoperative cognitive dysfunction after total joint arthroplasty in the elderly: a meta-analysis. *J Arthroplast.* (2014) 29:261–267.e1. doi: 10.1016/j.arth.2013.06.007

39. Cundy WJ, Theodoulou A, Ling CM, Krishnan J, Wilson CJ. Blood loss in Total knee arthroplasty. J Knee Surg. (2017) 30:452-9. doi: 10.1055/s-0036-1592147

40. Tao M, Zhang S, Han Y, Li C, Wei Q. Chen D, et al. Efficacy of transcranial direct current stimulation on postoperative delirium in elderly patients undergoing lower limb major arthroplasty: a randomized controlled trial. *Brain Stimul.* (2023) 16:88–96. doi: 10.1016/j.brs.2023.01.839